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Medical Center, Leiden, The NetherlandsIn this article, some results shown in Table S3; a paragraph of the
Results section; Fig. 2A(iii) and its related part in Fig. S6; and one
related sentence in the discussion are incorrect. During a routine
check of the results presented in this article, we realized that
patients with single organ (kidney, brain, or liver) failure or
dysfunction were wrongly classified owing to an error during
coding. Because of this, we computed wrong values for area
under the receiver-operating-characteristic curve (AUC) assess-
ing the discriminating accuracy of each metabolite inof original article: https://doi.org/10.1016/j.jhep.2019.11.009.
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Journal of Hepatology 20differentiating single organ failure/dysfunction from acute
decompensation (AD). We have now computed the correct AUC
values for single organ failure/dysfunction vs. AD. All other
computed values were correct, in particular the AUCs for ACLF,
and therefore these errors do not change our conclusion for the
differences in blood metabolome between patients with ACLF
and those with AD. Herein, we show the incorrect paragraph of
the Results section and sentence in the Discussion, and corre-
sponding corrected paragraph and sentence. The Results section,n (CRI), 16 rue Henri Huchard, 75890 PARIS cedex 18, France.
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Fig. S6, Table S3, and the Discussion have been corrected online
and in the printed version. In addition, we present the corrected
Fig. 2. below. We apologize for any inconvenience caused by
these late corrections.Results
Incorrect
The blood metabolite fingerprint is qualitatively similar in
patients with single organ dysfunction/failure independently
of the affected organ
To assess if there was a specific blood metabolite fingerprint for
each category of organ failure/organ dysfunction, we compared
patients with single liver-, brain- and kidney-failure/dysfunction
with patients with AD without any organ failure/dysfunction,
using metabolite AUCs [Fig. 2A(iii)]. The clinical phenotype and
number of patients included in this analysis is depicted in
Fig. S3C. The main finding of this analysis was that the finger-
print defining ACLF of any grade was also identified in the 3
categories of single organ failure/organ dysfunction, suggesting a
common metabolic derangement across different organs.Corrected
The blood metabolite fingerprint of ACLF differs across the
different categories of patients with single organ failure/
dysfunction
We compared patients with single liver-, brain- and kidney-
failure/dysfunction with patients with AD without any organ
failure/dysfunction, using metabolite AUCs [Fig. 2A(iii); Fig. S6;
Table S3]. The clinical phenotype and number of patients
included in this analysis is depicted in Fig. S3C. The main finding
of this analysis was that the fingerprint defining ACLF of any
grade was similarly present in patients with single kidney OF/OD
(with most values for AUC being of 0.75 or more), but was less
marked in those with single liver OF/OD (with most values for
AUC being between 0.70 and 0.75) and even absent in those with
brain OF/OD (with values of AUC ranging from 0.54 to 0.61).
These findings indicate differences in the contribution of indi-
vidual organs to the ACLF fingerprint; the kidney being a major
contributor followed by the liver to a lesser extent, while the
contribution of the brain was at most modest.Journal of Hepatology 20Discussion (First paragraph)
Incorrect
Of note, the ACLF fingerprint was independent of the type of
organ failure (phenotype).
Corrected
Of note, there were differences in the contribution of individual
organs to the ACLF fingerprint. The kidney was a major
contributor to the ACLF fingerprint followed by the liver to a
lesser extent, while the contribution of the brain was at most
modest.
Corrected Fig. 2. Identification of a unique ACLF-associated
blood metabolite fingerprint and its behavior in different
patients’ groups. (A) (i) Hierarchical cluster analysis of the
area under the receiver-operating-characteristic curve (AUCs)
assessing the discriminating accuracy of each of the 137
metabolites in differen-tiating ACLF from AD; (ii) Corre-
sponding metabolite AUC values in assessing ACLF-1, -2, and
-3, relative to AD; (iii) Corresponding metabolite AUC values
in assessing single failure/dysfunction of either the liver,
brain or kidney liver, relative to AD without any organ fail-
ure/dysfunction. Vertical violet bar identify the 38-metabo-
lite cluster highly associated with ACLF of any grade and
composing the ACLF-associated blood metabolite fingerprint.
AUCs for each metabolite were derived from a logistic
regression model (adjusted by age and sex) related to the
different comparisons. (B) The eigenmetabolite20 of the 38-
metabolite cluster across different groups, including healthy
subjects, patients with compensated cirrhosis, patients with
AD of cirrhosis (without ACLF) and patients with ACLF. (C)
The eigenmetabolite of the 38-metabolite cluster across four
groups: AD, ACLF-1, ACLF-2, ACLF-3. (D) The eigenmetabolite
of the 38-metabolite cluster across 3 groups: AD without any
organ failure/dysfunction, single kidney failure/dysfunction,
ACLF-2 or -3 without kidney failure/dysfunction. In (B), (C),
and (D) eignemetabolite values were compared using one-
way ANOVA, followed by Student’s t test. ACLF, acute-on-
chronic liver failure; AD, acute decompensation; HC, healthy
controls; KD, kidney dysfunction; KF, kidney failure; OD, or-
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